Ranking Profile - Lexicon Pharmaceuticals Inc

Introduction

Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company engaged in the development of sotagliflozin in type 1 diabetes, which was the subject of a separate NDA, in which NDA is in positive results of the third phase clinical trials evaluating the effect of sotagliflozin on type 1 diabetes in approximately 800, 800 and 1,400 patients. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin for heart failure and type 1 diabetes. Its clinical and preclinical development programs, LX9211, are meant for the treatment of diabetes and neuropathic pain, respectively. It has business collaborations with several pharmaceutical and biotechnology companies. The company operates an office in New Jersey and has a laboratory in Texas. Lexicon is headquartered at The Woodlands, Texas, the US.